These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 31333307)

  • 1. Hepatocellular carcinoma: Therapeutic advances in signaling, epigenetic and immune targets.
    Neureiter D; Stintzing S; Kiesslich T; Ocker M
    World J Gastroenterol; 2019 Jul; 25(25):3136-3150. PubMed ID: 31333307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities.
    Chen S; Cao Q; Wen W; Wang H
    Cancer Lett; 2019 Sep; 460():1-9. PubMed ID: 31207320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immune checkpoint therapy in liver cancer.
    Xu F; Jin T; Zhu Y; Dai C
    J Exp Clin Cancer Res; 2018 May; 37(1):110. PubMed ID: 29843754
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma.
    Dal Bo M; De Mattia E; Baboci L; Mezzalira S; Cecchin E; Assaraf YG; Toffoli G
    Drug Resist Updat; 2020 Jul; 51():100702. PubMed ID: 32371296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.
    Tagliamonte M; Mauriello A; Cavalluzzo B; Ragone C; Manolio C; Petrizzo A; Buonaguro L
    Cancer Lett; 2020 Mar; 473():25-32. PubMed ID: 31875523
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitors in hepatocellular carcinoma: A therapeutic perspective.
    Tsilimigras DI; Ntanasis-Stathopoulos I; Moris D; Spartalis E; Pawlik TM
    Surg Oncol; 2018 Dec; 27(4):611-618. PubMed ID: 30449480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers for hepatocellular carcinoma: What's new on the horizon?
    Ocker M
    World J Gastroenterol; 2018 Sep; 24(35):3974-3979. PubMed ID: 30254402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapy of hepatocellular carcinoma: present and future.
    Chan SL; Yeo W
    J Gastroenterol Hepatol; 2012 May; 27(5):862-72. PubMed ID: 22369685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunomodulatory Effects of Current Targeted Therapies on Hepatocellular Carcinoma: Implication for the Future of Immunotherapy.
    Lin YY; Tan CT; Chen CW; Ou DL; Cheng AL; Hsu C
    Semin Liver Dis; 2018 Nov; 38(4):379-388. PubMed ID: 30357775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current discovery strategies for hepatocellular carcinoma therapeutics.
    Dai Q; Zhang C; Yuan Z; Sun Q; Jiang Y
    Expert Opin Drug Discov; 2020 Feb; 15(2):243-258. PubMed ID: 31809618
    [No Abstract]   [Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
    Onuma AE; Zhang H; Huang H; Williams TM; Noonan A; Tsung A
    Gene Expr; 2020 Jun; 20(1):53-65. PubMed ID: 32340652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocellular carcinoma treatment over sorafenib: epigenetics, microRNAs and microenvironment. Is there a light at the end of the tunnel?
    Gnoni A; Santini D; Scartozzi M; Russo A; Licchetta A; Palmieri V; Lupo L; Faloppi L; Palasciano G; Memeo V; Angarano G; Brunetti O; Guarini A; Pisconti S; Lorusso V; Silvestris N
    Expert Opin Ther Targets; 2015; 19(12):1623-35. PubMed ID: 26212068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy of Hepatocellular Carcinoma.
    Heinrich B; Czauderna C; Marquardt JU
    Oncol Res Treat; 2018; 41(5):292-297. PubMed ID: 29705790
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HDAC inhibitors in liver cancer: which route to take?
    Kiesslich T; Neureiter D
    Expert Rev Gastroenterol Hepatol; 2019 Jun; 13(6):515-517. PubMed ID: 30991854
    [No Abstract]   [Full Text] [Related]  

  • 15. Novel immunotherapeutic approaches for hepatocellular carcinoma treatment.
    Busato D; Mossenta M; Baboci L; Di Cintio F; Toffoli G; Dal Bo M
    Expert Rev Clin Pharmacol; 2019 May; 12(5):453-470. PubMed ID: 30907177
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immuno-oncology for Hepatocellular Carcinoma: The Present and the Future.
    Armstrong SA; He AR
    Clin Liver Dis; 2020 Nov; 24(4):739-753. PubMed ID: 33012456
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Next Generation of Preclinical Liver Cancer Models.
    Weber A; O'Connor T; Heikenwalder M
    Clin Cancer Res; 2015 Oct; 21(19):4254-6. PubMed ID: 26169964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sorafenib-based combined molecule targeting in treatment of hepatocellular carcinoma.
    Gao JJ; Shi ZY; Xia JF; Inagaki Y; Tang W
    World J Gastroenterol; 2015 Nov; 21(42):12059-70. PubMed ID: 26576091
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting tyrosine kinase receptors in hepatocellular carcinoma.
    Muntané J; De la Rosa AJ; Docobo F; García-Carbonero R; Padillo FJ
    Curr Cancer Drug Targets; 2013 Mar; 13(3):300-12. PubMed ID: 23016985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse Models of Oncoimmunology in Hepatocellular Carcinoma.
    Bresnahan E; Lindblad KE; Ruiz de Galarreta M; Lujambio A
    Clin Cancer Res; 2020 Oct; 26(20):5276-5286. PubMed ID: 32327473
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.